BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.

BACKGROUND: A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS).

CONCLUSIONS: CYC demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent anaplastic astrocytoma, all of whom had failed prior TMZ chemotherapy.

[MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. DACARBAZINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2005 American Cancer Society.

(PMID = 16323194.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.

BACKGROUND: The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS).

[MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18361434.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion.

The histological diagnosis was anaplastic astrocytoma.

Malignant glioma with exophytic growth in the temporal lobe should be considered in the differential diagnosis of isolated oculomotor nerve paresis.

[MeSH-major] Astrocytoma / complications. Oculomotor Nerve Diseases / etiology. Supratentorial Neoplasms / complications. Temporal Lobe

[MeSH-minor] Adult. Astrocytes / pathology. Biomarkers, Tumor / analysis. Brain Stem / pathology. Cerebral Arteries / pathology. Cisterna Magna / pathology. Dominance, Cerebral / physiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / etiology. Nerve Compression Syndromes / pathology. Nerve Compression Syndromes / surgery. Neuronavigation. Oculomotor Nerve / pathology. Oculomotor Nerve / surgery. Pons / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16636512.001).

[ISSN] 0470-8105

[Journal-full-title] Neurologia medico-chirurgica

[ISO-abbreviation] Neurol. Med. Chir. (Tokyo)

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic pleomorphic xanthoastrocytoma with a component of anaplastic astrocytoma presenting as skull base tumor followed by downward extracranial extension. Case report.

Histological examination revealed cellular pleomorphism with mitotic activity, focal necrosis, but lacking endothelial proliferation, consistent with anaplastic pleomorphic xanthoastrocytoma (PXA) with component of anaplastic astrocytoma.

PXA with anaplastic appearance may have a component of anaplastic astrocytoma with more aggressive behavior.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Skull Base Neoplasms / pathology

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21206189.001).

[ISSN] 1349-8029

[Journal-full-title] Neurologia medico-chirurgica

[ISO-abbreviation] Neurol. Med. Chir. (Tokyo)

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma.

Using PCR-SSCP and gene sequencing, we analyzed the TP53 and TP73 genes in a case of a grade III anaplastic astrocytoma that progressed to glioblastoma.

[MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19876867.001).

[ISSN] 1676-5680

[Journal-full-title] Genetics and molecular research : GMR

[ISO-abbreviation] Genet. Mol. Res.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Brazil

[Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.

BACKGROUND: Anaplastic astrocytoma (AA) and its more aggressive counterpart, glioblastoma multiforme (GBM), are the most common intrinsic brain tumors in adults and are almost universally fatal.

A deeper understanding of the molecular relationship of these tumor types is necessary to derive insights into the diagnosis, prognosis, and treatment of gliomas.

These feature lists could be utilized to aid in diagnosis, prognosis, and grade reduction of high-grade gliomas and to identify genes that were not previously suspected of playing an important role in glioma biology.

Genetic Alliance. consumer health - Glioblastoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Cancer. 1999 Dec;81(8):1371-7 [10604735.001]

[Cites] Mol Endocrinol. 2000 Jun;14(6):848-62 [10847587.001]

[Cites] J Biol Chem. 2000 Jul 7;275(27):20315-23 [10783396.001]

[Cites] BMC Bioinformatics. 2008;9:63 [18226260.001]

[Cites] Genomics. 2008 May;91(5):395-406 [18343632.001]

[Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]

[Cites] Biochem Biophys Res Commun. 2008 Sep 5;373(4):539-44 [18590702.001]

[Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]

[Cites] BMC Bioinformatics. 2009;10:1 [19118496.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]

[Cites] FASEB J. 2001 Feb;15(2):458-66 [11156961.001]

[Cites] Am J Pathol. 2002 Apr;160(4):1279-92 [11943713.001]

[Cites] Cancer Res. 2002 Aug 1;62(15):4427-33 [12154050.001]

[Cites] Am J Pathol. 2002 Nov;161(5):1695-700 [12414516.001]

[Cites] Cancer Res. 2002 Nov 1;62(21):6205-10 [12414648.001]

[Cites] Acta Neuropathol. 2003 Jan;105(1):49-57 [12471461.001]

[Cites] Pancreas. 2003 Jan;26(1):56-64 [12499918.001]

[Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]

[Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]

[Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]

[Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]

[Cites] Genome Biol. 2003;4(4):210 [12702200.001]

[Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]

[Cites] Bioinformatics. 2003;19 Suppl 1:i84-90 [12855442.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]

[Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]

[Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]

[Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]

[Cites] Nat Biotechnol. 2004 May;22(5):615-21 [15122300.001]

[Cites] FEBS Lett. 2004 Aug 27;573(1-3):83-92 [15327980.001]

[Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]

[Cites] Genome Biol. 2004;5(10):R80 [15461798.001]

[Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]

[Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]

[Cites] Cancer Res. 1999 Feb 15;59(4):895-900 [10029081.001]

[Cites] Cancer Res. 1999 Aug 15;59(16):3915-8 [10463582.001]

[Cites] BMC Bioinformatics. 2004 Oct 25;5:159 [15504239.001]

[Cites] Bioinformatics. 2004 Nov 22;20(17):3166-78 [15231529.001]

[Cites] Genome Biol. 2005;6(2):R16 [15693945.001]

[Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]

[Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]

[Cites] Nat Methods. 2005 May;2(5):345-50 [15846361.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9 [16174746.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]

[Cites] J Bioinform Comput Biol. 2005 Oct;3(5):1171-89 [16278953.001]

[Cites] Nat Rev Genet. 2006 Jan;7(1):55-65 [16369572.001]

[Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]

[Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]

[Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]

[Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]

[Cites] Biom J. 2006 Jun;48(3):435-50 [16845907.001]

[Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]

[Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]

[Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]

[Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41 [17606927.001]

[Cites] Cancer Res. 2007 Nov 1;67(21):10296-303 [17974971.001]

[Cites] Neurosurg Rev. 2008 Jan;31(1):83-9; discussion 89-90 [17917751.001]

[Cites] Comput Biol Chem. 2008 Feb;32(1):38-46 [17988949.001]

[Cites] Bioinformatics. 2008 Feb 1;24(3):374-82 [18204063.001]

[Cites] Ann Vasc Surg. 2008 Mar;22(2):273-84 [18346582.001]

(PMID = 19732454.001).

[ISSN] 1476-4598

[Journal-full-title] Molecular cancer

[ISO-abbreviation] Mol. Cancer

[Language] ENG

[Grant] United States / NIGMS NIH HHS / GM / R01 GM082798; United States / NIH HHS / OD / DP2 OD002319; United States / NIH HHS / OD / DP2OD002319; United States / NLM NIH HHS / LM / U54 LM008748; United States / NLM NIH HHS / LM / U54LM008748

[Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A

[Other-IDs] NLM/ PMC2743637

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma.

A case of spontaneous, painless partial III (pupil-sparing) and IV fascicular nerve paresis as the first presentation of anaplastic astrocytoma is reported.

[MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Oculomotor Nerve Diseases / etiology

[MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Eye Movements. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiologe. 1999 Oct;39(10):821-7 [10550380.001]

[Cites] Acta Neurochir (Wien). 1979;49(1-2):35-45 [230705.001]

[Cites] J Clin Neurosci. 2005 Nov;12(8):946-9 [16326274.001]

[Cites] Neurol Neurochir Pol. 1983 Jul-Aug;17(4):471-5 [6646330.001]

[Cites] Neurosurgery. 1982 Apr;10(4):437-44 [7099393.001]

(PMID = 17951905.001).

[ISSN] 0301-4738

[Journal-full-title] Indian journal of ophthalmology

[ISO-abbreviation] Indian J Ophthalmol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC2635986

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary anaplastic pilocytic astrocytoma.

We report two adult patients with pilocytic astrocytomas with anaplastic features at initial diagnosis.

Pilocytic astrocytomas are low-grade astrocytomas that occur rarely in adults.

Initial presentation of a pilocytic astrocytoma with anaplastic features is particularly uncommon and making a definitive diagnosis of pilocytic astrocytoma with anaplastic features can be challenging.

It is critical to differentiate glioblastoma (World Health Organization [WHO] grade 4) and pilocytic astrocytoma with anaplastic features (WHO grade 3) from pilocytic astrocytoma (WHO grade 1) as there are significant therapeutic and prognostic implications.

Improved therapeutic strategies are required for pilocytic astrocytomas with anaplastic features.

[MeSH-major] Anaplasia / complications. Astrocytoma / complications. Brain Neoplasms / complications

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Pilocytic astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19815416.001).

[ISSN] 1532-2653

[Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

[ISO-abbreviation] J Clin Neurosci

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Scotland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic astrocytoma in adults.

Anaplastic astrocytoma is an uncommon disease in the adult population.

Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.

In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for anaplastic astrocytoma .

Hazardous Substances Data Bank. DACARBAZINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17478095.001).

[ISSN] 1040-8428

[Journal-full-title] Critical reviews in oncology/hematology

[ISO-abbreviation] Crit. Rev. Oncol. Hematol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Review

[Publication-country] Ireland

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide

[Number-of-references] 69

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?

We report the case of a 28-year-old man who presented simultaneously with acromegaly and an anaplastic astrocytoma, which had rapidly progressed from a low-grade astrocytoma.

The coexistence of systemic IGF-I hypersecretion with a quick progression in the histopathological grade of the astrocytoma raises the compelling question of whether the clinical behavior of the astrocytic tumor was influenced by the acromegalic status.

[MeSH-major] Acromegaly / complications. Astrocytoma / complications. Brain Neoplasms / complications

Genetic Alliance. consumer health - Acromegaly.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]

[Cites] Horm Metab Res. 1999 Feb-Mar;31(2-3):114-9 [10226790.001]

[Cites] Cancer Res. 1991 Oct 1;51(19):5107-12 [1717138.001]

[Cites] Ann Neurol. 1992 Apr;31(4):431-6 [1586143.001]

[Cites] Neurosurgery. 1998 Jan;42(1):172-8 [9442520.001]

[Cites] J Neurooncol. 1997 Aug;34(1):31-5 [9210051.001]

[Cites] Eur J Endocrinol. 2003 Nov;149(5):377-92 [14585082.001]

[Cites] Cancer Res. 1994 Apr 15;54(8):2218-22 [8174129.001]

[Cites] J Neurooncol. 1997 Dec;35(3):315-25 [9440028.001]

[Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]

[Cites] Neurosurgery. 1992 Oct;31(4):636-42; discussion 642 [1407448.001]

[Cites] BMC Cancer. 2002 May 31;2:15 [12057025.001]

[Cites] Neuro Oncol. 1999 Apr;1(2):109-19 [11550306.001]

[Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]

[Cites] Clin Endocrinol (Oxf). 2001 Dec;55(6):731-3 [11895213.001]

[Cites] Growth Horm IGF Res. 2001 Apr;11(2):84-91 [11472074.001]

[Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):199-209 [2164527.001]

[Cites] Endocr Rev. 2005 Dec;26(7):916-43 [16131630.001]

[Cites] J Neuropathol Exp Neurol. 2004 Jan;63(1):13-9 [14748557.001]

[Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]

[Cites] Clin Cancer Res. 1999 May;5(5):1025-33 [10353735.001]

[Cites] Exp Cell Res. 1988 Jun;176(2):336-43 [2837402.001]

[Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4444-9 [11134091.001]

[Cites] Cancer Res. 1987 Nov 1;47(21):5758-64 [2889527.001]

[Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]

[Cites] Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399 [12762884.001]

[Cites] Neurosurgery. 1996 Dec;39(6):1243-5; discussion 1245-6 [8938782.001]

[Cites] Neurobiol Dis. 2000 Dec;7(6 Pt B):657-65 [11114263.001]

[Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 [12107213.001]

[Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]

[Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):115-22 [11947942.001]

(PMID = 18000757.001).

[ISSN] 1386-341X

[Journal-full-title] Pituitary

[ISO-abbreviation] Pituitary

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Ergolines; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; LL60K9J05T / cabergoline

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.

Serum samples from 61 newly diagnosed patients with brain tumours and 50 age- and sex-matched non-tumour controls were analysed by ELISA for circulating levels of interleukin-12 (IL-12p70 and p40) and interleukin-10 (IL-10); pivotal Th1 and Th2 cytokines, respectively.

Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).

Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.

Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.

This study shows that patients with advanced primary intracranial malignancies have decreased circulating IL-12 and increased circulating IL-10, demonstrating that brain tumours have a major systemic effect on the immune system.

[MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology

Genetic Alliance. consumer health - Glioblastoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Meningioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16685388.001).

[ISSN] 1021-335X

[Journal-full-title] Oncology reports

[ISO-abbreviation] Oncol. Rep.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

[Chemical-registry-number] 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Congenital anaplastic astrocytoma differentiated into pilocytic astrocytoma: an autopsy case.

We report an autopsy case of congenital astrocytoma and its histopathological changes during 5 years of the patient's development from birth to death.

The right orbital tumor, which was enucleated at 2 months of age, was a highly cellular tumor with moderate pleomorphism resembling anaplastic astrocytoma.

On the other hand, at autopsy, a brain tumor was found in the right diencephalic region with features of pilocytic astrocytoma, accompanied by leptomeningeal dissemination.

A biopsy specimen, which was obtained from the chiasmatic part of the tumor at 4 months of age, showed an intermediate appearance between the orbital tumor and the brain tumor obtained at autopsy.

We believe that this congenital anaplastic astrocytoma differentiated into a pilocytic astrocytoma during the 5 years of the patient's development.

The transformation of the congenital astrocytoma from anaplastic to pilocytic forms can be attributed to the nature of the tumor, namely postmitotic neoplastic cells are characterized by their ability to undergo self-differentiation, along with the organotropism of the developing brain.

[MeSH-major] Astrocytoma / congenital. Astrocytoma / pathology. Brain Neoplasms / congenital. Brain Neoplasms / pathology

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Pilocytic astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18282169.001).

[ISSN] 0919-6544

[Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology

[ISO-abbreviation] Neuropathology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic astrocytoma with eosinophilic granular cells.

Thus, the tumor was histologically diagnosed as anaplastic astrocytoma.

The present case should also be discriminated from granular cell astrocytoma.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18018480.001).

[ISSN] 0919-6544

[Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology

[ISO-abbreviation] Neuropathology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).

Bevacizumab-related toxicity included fatigue (14 patients; 2 grade 3), leukopenia (7; 1 grade 3), deep vein thrombosis (5; 2 grade 3), hypertension (5; 1 grade 3), anemia (4; 0 grade 3) and wound dehiscence (1; 1 grade 3).

[MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]

[Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]

[Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]

[Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]

[Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]

[Cites] Neuro Oncol. 2004 Jul;6(3):253-8 [15279718.001]

[Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]

[Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]

[Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]

[Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

[Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]

[Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]

[Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]

[Cites] Stat Med. 1991 May;10(5):749-55 [2068428.001]

[Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]

[Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]

[Cites] Surg Neurol. 1993 Jun;39(6):538-43 [8390727.001]

[Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]

[Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]

[Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]

[Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]

[Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]

[Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]

[Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]

[Cites] J Neurosurg. 1990 Apr;72 (4):583-8 [2319317.001]

[Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6 [1651302.001]

[Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]

[Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]

[Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):3-8 [1572829.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]

[Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]

[Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):593-7 [1429080.001]

[Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]

[Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]

[Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]

[Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]

(PMID = 18953491.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma.

The incidence of hemorrhagic onset in pilocytic astrocytoma and pilomyxoid astrocytoma, and the clinical and histological characteristics, were compared to other types of neuroepithelial tumors or nonhemorrhagic pilocytic astrocytoma by retrospective review of 445 consecutive neuroepithelial tumors treated at our institute.

Hemorrhagic onset was observed in 4 of 35 (11.4%) patients with pilocytic astrocytoma and pilomyxoid astrocytoma, with higher incidence than in glioblastoma (3.9%), anaplastic oligodendroglioma (7.7%), and anaplastic ependymoma (7.1%).

The hemorrhagic onset occurred in 2 patients with sporadic pilocytic astrocytoma, 1 with pilocytic astrocytoma associated with neurofibromatosis type 1, and 1 with pilomyxoid astrocytoma.

Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma is not as uncommon as was previously thought, so pilocytic astrocytoma or pilomyxoid astrocytoma should be considered in the differential diagnosis of patients with brain tumors manifesting as hemorrhagic onset.

[MeSH-major] Astrocytoma / complications. Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Intracranial Hemorrhages / etiology. Intracranial Hemorrhages / pathology

[MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Capillaries / pathology. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / pathology. Paralysis / etiology. Tomography, X-Ray Computed. Young Adult

Genetic Alliance. consumer health - Pilocytic astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19408090.001).

[ISSN] 1861-387X

[Journal-full-title] Brain tumor pathology

[ISO-abbreviation] Brain Tumor Pathol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Ki-67 Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multicentric anaplastic astrocytoma in a child.

We report a rare case of anaplastic astrocytoma with multicentric central nervous system lesions in a 10-year-old girl presenting with a 1-month history of progressive headache and paraparesis.

Neurological examination upon admission revealed papilloedema of both eyes and grade 2/5 weakness of both legs.

The histological diagnosis was anaplastic astrocytoma based on the WHO classification.

Despite being an uncommon disease in children and being associated with an unfavourable long-term outcome, early diagnosis and appropriate management of this condition may contribute to reduced patient morbidity.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Spinal Cord Neoplasms / pathology

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17161293.001).

[ISSN] 0967-5868

[Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

[ISO-abbreviation] J Clin Neurosci

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Scotland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic astrocytoma presenting as reversible posterior leukoencephalopathy syndrome.

We report a 60-year-old man with grade III astrocytoma, who presented with status epilepticus.

The initial MRI did not demonstrate typical findings of an astrocytoma but rather showed reversible posterior leukoencephalopathy syndrome (RPLS).

A brain tumor should be considered and the patient carefully followed by MRI, even if the MRI white matter lesion pattern suggests RPLS.

[MeSH-major] Astrocytoma / diagnosis. Brain Diseases / diagnosis. Occipital Lobe / pathology

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17122727.001).

[ISSN] 1074-7931

[Journal-full-title] The neurologist

[ISO-abbreviation] Neurologist

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells.

OBJECTIVE: The number of evidences regarding the role of tumor stem cells (TSC) in the initiation and progression of high-grade astrocytomas became more and more numerous in the last years.

This issue has been intensively tested in glioblastoma, but little attention has been paid for anaplastic astrocytoma.

The main objective of this paper was to study the morphological characteristics of the xenografts developed from glioblastoma and anaplastic astrocytoma derived cancer stem cells.

METHODS: The authors of this study successfully isolated and partial characterized primary cultures of glioblastoma and anaplastic astrocytoma derived TSC.

RESULTS: The tumor xenografts which have been established in nude mice using TSC had different characteristics when compared with U87 xenografts previously developed by our group, and depend of the origin type of the tumors (glioblastoma versus anaplastic astrocytoma).

The diffuse growing pattern and cells infiltration have been more pronounced in both anaplastic astrocytoma and glioblastoma derived TSC xenografts compared with U87 line xenografts.

CONCLUSION: Our results support the hypothesis regarding the role of TSC in the infiltration process of glioblastoma and anaplastic astrocytoma.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplastic Stem Cells / pathology. Transplantation, Heterologous

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21141095.001).

[ISSN] 1221-9118

[Journal-full-title] Chirurgia (Bucharest, Romania : 1990)

[ISO-abbreviation] Chirurgia (Bucur)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Romania

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma.

INTRODUCTION: Malignant brain tumors have been reported to occur after childhood irradiation more frequently than in the nonirradiated population.

DISCUSSION: In this study, we report the case of a 15-year-old boy treated for medulloblastoma with surgery and craniospinal radiotherapy, who developed a meningioma 18 years after initial treatment and subsequently an anaplastic astrocytoma 23 years after primary treatment.

The patient is currently alive but with recurrent astrocytoma after a complete remission on temozolomide monotherapy.

[MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Medulloblastoma / radiotherapy. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Medulloblastoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]

[Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]

[Cites] J Neurosurg. 1989 Mar;70(3):469-74 [2536806.001]

[Cites] Ann Neurol. 1978 Oct;4(4):319-21 [727737.001]

[Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]

[Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]

[Cites] Childs Nerv Syst. 2004 Apr;20(4):243-6 [14704813.001]

[Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]

[Cites] Lancet. 1997 May 10;349(9062):1369 [9149706.001]

[Cites] J Pediatr Endocrinol Metab. 2003 Jan;16(1):97-101 [12585346.001]

[Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]

[Cites] Clin Neuropathol. 1994 Sep-Oct;13(5):281-5 [7805312.001]

[Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]

[Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]

[Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]

[Cites] J Neurosurg. 1978 Apr;48(4):622-7 [632887.001]

[Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]

[Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]

[Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]

[Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]

[Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]

[Cites] Acta Neurochir (Wien). 2001;143(7):697-700 [11534690.001]

[Cites] J Neuroradiol. 1983;10 (1):43-9 [6864263.001]

[Cites] Neurology. 1981 May;31(5):616-9 [7194977.001]

[Cites] Neurosurgery. 1980 May;6(5):546-51 [6251397.001]

[Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]

[Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]

[Cites] Clin Neurol Neurosurg. 1998 Mar;100(1):56-9 [9637208.001]

[Cites] Can J Neurol Sci. 1984 Nov;11(4):475-8 [6518432.001]

[Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]

[Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]

[Cites] Onkologie. 2001 Feb;24(1):66-72 [11441284.001]

[Cites] Eur J Paediatr Neurol. 1999;3(4):177-80 [10476368.001]

[Cites] Can J Neurol Sci. 1992 Nov;19(4):498-503 [1330262.001]

[Cites] J Neurosurg. 1978 Sep;49(3):445-9 [682008.001]

[Cites] Am J Public Health Nations Health. 1966 Dec;56(12):2114-20 [5334312.001]

[Cites] Cancer. 1979 Jan;43(1):129-36 [104784.001]

[Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6 [11878577.001]

(PMID = 16570196.001).

[ISSN] 0256-7040

[Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

[ISO-abbreviation] Childs Nerv Syst

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Germany

[Number-of-references] 40

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does vasculogenic mimicry exist in astrocytoma?

It is unknown whether a similar VM phenomenon exists in astrocytoma.

The present study was to examine 45 astrocytomas (including World Health Organization grade II 15 cases, grade III 15 cases, and grade IV 15 cases) by CD34 endothelial marker periodic acid-Schiff (PAS) dual staining to see if VM existing in these tumors.

PAS-positive pattern of VM was found in two grade IV astrocytomas.

Furthermore, in astrocytoma, especially glioblastoma, focus of anaplastic tumor cells appeared with CD34 expression, whereas some tumor cells lost glial fibrillary acid protein expression.

It is assumed that genetically deregulated tumor cells in astrocytoma could lose the astrocyte-specific protein and express inappropriate markers not expected in cells of astrocyte lineage.

The present results suggest that VM phenomenon exists in some malignant astrocytoma.

[MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15923371.001).

[ISSN] 0022-1554

[Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

[ISO-abbreviation] J. Histochem. Cytochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Coloring Agents; 0 / Schiff Bases; 10450-60-9 / Periodic Acid

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary glioblastomas and anaplastic astrocytoma in a glioma family.

A 72-year-old man presented with a short duration of symptoms relating to a right fronto-parietal glioblastoma and a family history of children with brain tumours.

Analysis of the patient's family tree revealed that out of seven children, he had a living son with anaplastic astrocytoma, a daughter who had died with a glioblastoma, and a son who had died with a histologically undiagnosed intrinsic brain tumour.

One niece was also thought to have died from a brain tumour.

There is no clinical evidence to support a diagnosis of a multiple cancer or neurocutaneous syndrome in this family.

In view of what is known about the genetics of familial glioma, it is interesting to note the clinical evidence of both 'primary' glioblastoma and anaplastic astrocytoma in the same kindred.

[MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Family Health. Glioblastoma / genetics

Genetic Alliance. consumer health - Glioma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16678736.001).

[ISSN] 0967-5868

[Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

[ISO-abbreviation] J Clin Neurosci

[Language] eng

[Publication-type] Case Reports; Comparative Study; Journal Article

[Publication-country] Scotland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic oligodendroglioma and oligoastrocytoma.

Until approximately 15 years ago, the diagnosis of an oligodendroglioma (OD) was merely as a pathologic entity.

The only clinical relevant meaning of this histologic diagnosis was the observation that the prognosis of OD was in general better than that of astrocytic tumors of similar grade.

Observations have led to the current tendency to consider 1p/19q loss low-grade and anaplastic oligodendroglioma a separate biologic entity, at least within clinical trials, since they have a much better outcome.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology

Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.

Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.

Genetic Alliance. consumer health - Oligoastrocytoma.

Genetic Alliance. consumer health - Oligodendroglioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for oligoastrocytoma .

Hazardous Substances Data Bank. LOMUSTINE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17964027.001).

[ISSN] 0733-8619

[Journal-full-title] Neurologic clinics

[ISO-abbreviation] Neurol Clin

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine

[Number-of-references] 75

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.

This report presents a 70-year-old male who presented with a rare malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.

[MeSH-minor] Aged. Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Humans. Magnetic Resonance Imaging / methods. Male

Genetic Alliance. consumer health - Histiocytosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19766005.001).

[ISSN] 1532-2653

[Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

[ISO-abbreviation] J Clin Neurosci

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Scotland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma].

BACKGROUND: Anaplastic astrocytomas in neonates are extremely rare.

An ultrasound scan of the brain showed an intracerebral bleeding.

No tumour was found, but an anaplastic astrocytoma (WHO Grade III) was diagnosed histologically.

Serial ultrasound investigations of the brain showed a normal midline and a redevelopment of the left-sided ventricle.

CONCLUSION: Congenital anaplastic astrocytomas have a variable outcome, with different survival rates as compared to adults.

[MeSH-major] Astrocytoma / congenital. Brain Neoplasms / congenital. Cerebral Hemorrhage / congenital

[MeSH-minor] Diagnosis, Differential. Echoencephalography. Fatal Outcome. Female. Humans. Infant, Newborn. Magnetic Resonance Imaging. Occipital Lobe / pathology. Temporal Lobe / pathology. Tomography, X-Ray Computed. Trephining

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18956278.001).

[ISSN] 0948-2393

[Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie

[ISO-abbreviation] Z Geburtshilfe Neonatol

[Language] ger

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases.

OBJECT: The purpose of this retrospective study was to estimate the prognostic impact of treatment parameters for 170 patients with anaplastic astrocytoma (AA).

[MeSH-major] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17432706.001).

[ISSN] 0022-3085

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease.

INTRODUCTION: Ollier Disease is a sporadic skeletal disorder with a predisposition to oncogenesis.

We are presenting a young patient with Ollier Disease and high-grade astrocytoma.

Brain MRI with contrast showed a 41 x 55 mm mass in the posterior fossa with spotty enhancement, which pathology proved to be anaplastic astrocytoma.

[MeSH-major] Astrocytoma / etiology. Astrocytoma / pathology. Cerebellar Neoplasms / etiology. Cerebellar Neoplasms / pathology. Cerebellum / pathology. Enchondromatosis / complications

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Ollier disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Pathol. 2005 Sep;167(3):859-67 [16127163.001]

[Cites] J Laryngol Otol. 2001 Oct;115(10 ):845-7 [11668006.001]

[Cites] Orphanet J Rare Dis. 2006 Sep 22;1:37 [16995932.001]

[Cites] Saudi Med J. 2004 Sep;25(9):1261-3 [15448780.001]

[Cites] AJR Am J Roentgenol. 2001 Feb;176(2):289-96 [11159059.001]

[Cites] Cancer Genet Cytogenet. 2003 May;143(1):1-31 [12742153.001]

[Cites] Childs Nerv Syst. 1999 May;15(5):222-5 [10392492.001]

[Cites] Am J Med Genet A. 2004 Oct 1;130A(2):123-7 [15372512.001]

[Cites] Brain Res. 2000 Jun 23;868(2):230-40 [10854575.001]

[Cites] J Bone Joint Surg Am. 1987 Feb;69(2):269-74 [3805090.001]

[Cites] Clin Neurol Neurosurg. 1999 Jun;101(2):106-10 [10467905.001]

(PMID = 18414790.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / PTH1R protein, human; 0 / Receptor, Parathyroid Hormone, Type 1; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size.

Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III.

We examined a series of 120 astrocytomas including 70 pilocytic astrocytomas WHO grade I and 50 diffuse astrocytomas WHO grade II for both, BRAF-KIAA1549 fusion with a newly developed FISH assay and mutations in IDH1 and IDH2 by direct sequencing.

Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions.

Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma.

[MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Isocitrate Dehydrogenase / genetics. Proto-Oncogene Proteins B-raf / genetics

[MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Tissue Array Analysis

Genetic Alliance. consumer health - Diffuse Astrocytoma.

Genetic Alliance. consumer health - Pilocytic astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19543740.001).

[ISSN] 1432-0533

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42 / isocitrate dehydrogenase (NADP+); EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report.

The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.

Histological examination revealed anaplastic oligodendroglioma in the parietal lobe and anaplastic astrocytoma in the insula.

One year later, the anaplastic astrocytoma was found to have transformed into a glioblastoma multiforme.

Fluorescence in situ hybridization analysis and immunohistochemical examinations detected deletions of the lp36 and 19q13 loci, and nuclear accumulation of TP53 protein in the anaplastic oligodendroglioma but not in the glioblastoma multiforme.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology

Genetic Alliance. consumer health - Central Neurocytoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.

Genetic Alliance. consumer health - Oligodendroglioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17639893.001).

[ISSN] 0022-3085

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma.

Diagnosis of an anaplastic astrocytoma (World Health Organization grade III) is associated with a highly variable prognosis.

In this study, we analysed 48 patients with a histological diagnosis of anaplastic astrocytoma and found peritumoral post-gadolinium contrast enhancement to be a clear prognostic marker of poor prognosis.

The survival differences observed in the enhancing and non-enhancing lesions in patients diagnosed with anaplastic astrocytoma supports the existence of a broad anaplastic spectrum of disease, with enhancement being a clinical marker of tumour progression along this spectrum.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gadolinium. Image Enhancement

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.

(PMID = 20605464.001).

[ISSN] 1532-2653

[Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

[ISO-abbreviation] J Clin Neurosci

[Language] eng

[Publication-type] Journal Article

[Publication-country] Scotland

[Chemical-registry-number] AU0V1LM3JT / Gadolinium

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Extraneural metastases of anaplastic oligodendroglial tumors.

According to the literature, they tend to appear in glioblastoma patients, but are exceptionally rare in anaplastic oligodendroglioma.

We report on an anaplastic oligodendroglioma and an anaplastic oligoastrocytoma that metastasized to cervical lymph nodes and bones.

In the second case, metastases to the sacrum and femur developed after surgery for a recurrent anaplastic oligoastrocytoma.

Our two cases reconfirm a rare but definite ability not only of glioblastoma but also of anaplastic oligodendroglioma, namely to metastasize to extraneural sites.

It is important to bear this in mind, particularly in cases when the history of primary brain tumor is unavailable.

In such instances, the correct diagnosis of the metastatic lesion may be extremely difficult if not impossible.

[MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Femoral Neoplasms / secondary. Neoplasm Recurrence, Local. Oligodendroglia / pathology. Oligodendroglioma / secondary. Sacrum / pathology. Spinal Neoplasms / secondary

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19410385.001).

[ISSN] 1618-0631

[Journal-full-title] Pathology, research and practice

[ISO-abbreviation] Pathol. Res. Pract.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic factors for anaplastic astrocytomas.

Anaplastic astrocytomas (WHO grade III) constitute about 10% of all gliomas.

Currently, only few factors have been identified as useful for prognosis of anaplastic astrocytoma: age and Karnofsky Performance Status.

[MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Brain Neoplasms / pathology

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]

[Cites] Clin Cancer Res. 2003 Apr;9(4):1461-8 [12684420.001]

[Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]

[Cites] J Clin Oncol. 2006 Jan 10;24(2):213-6 [16365177.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]

[Cites] J Neurooncol. 2005 Jan;71(2):85-9 [15690121.001]

[Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64 [16267128.001]

[Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]

[Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]

[Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]

[Cites] Cancer. 1999 Aug 15;86(4):672-83 [10440696.001]

[Cites] Clin Cancer Res. 2004 Aug 1;10 (15):4933-8 [15297393.001]

[Cites] Neurosurgery. 1991 Apr;28(4):496-501 [1851971.001]

[Cites] Cancer Res. 1998 Oct 15;58(20):4694-700 [9788624.001]

[Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]

[Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]

[Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]

[Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]

[Cites] Proteomics. 2005 Mar;5(4):1167-77 [15759318.001]

[Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]

[Cites] Neurosurgery. 1992 Oct;31(4):636-42; discussion 642 [1407448.001]

[Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]

[Cites] CA Cancer J Clin. 1990 Jan-Feb;40(1):9-26 [2104569.001]

[Cites] J Neuropathol Exp Neurol. 1996 Jan;55(1):81-7 [8558174.001]

[Cites] Am J Hum Genet. 1996 Jun;58(6):1260-7 [8651304.001]

[Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]

[Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]

[Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]

[Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]

[Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]

[Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):319-31 [10931365.001]

[Cites] Neuroradiology. 1997 May;39(5):348-50 [9189880.001]

[Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]

[Cites] Neurosurgery. 2004 Feb;54(2):349-57; discussion 357 [14744281.001]

[Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]

[Cites] Oncogene. 1995 Jun 1;10(11):2243-6 [7784070.001]

[Cites] Genes Chromosomes Cancer. 1995 Jun;13(2):86-93 [7542911.001]

[Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]

[Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):823-35 [15928303.001]

[Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):249-58 [15671553.001]

[Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]

[Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]

[Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]

[Cites] J Neurooncol. 2002 Jul;58(3):203-15 [12187956.001]

[Cites] Genes Chromosomes Cancer. 1998 Mar;21(3):195-206 [9523194.001]

[Cites] Oncogene. 1996 Sep 5;13(5):983-94 [8806688.001]

[Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]

[Cites] Cancer. 2005 Dec 15;104(12):2775-83 [16284993.001]

[Cites] J Neurooncol. 2004 Jul;68(3):275-83 [15332332.001]

[Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74 [16286386.001]

[Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]

(PMID = 17001519.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Number-of-references] 55

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report.

Gliosarcoma is an uncommon malignant brain tumor composed of distinct sarcomatous and malignant glial cell elements.

We report a rare case with gliosarcomatous recurrence of anaplastic astrocytoma with neurofibromatosis type 1 (NF-1) followed by chemoradiation therapy.

Histopathology of the tumor showed findings corresponding with anaplastic astrocytoma.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neurofibromatosis 1 / pathology

Genetic Alliance. consumer health - Gliosarcoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Neurofibromatosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2010 Elsevier B.V. All rights reserved.

(PMID = 20466481.001).

[ISSN] 1872-6968

[Journal-full-title] Clinical neurology and neurosurgery

[ISO-abbreviation] Clin Neurol Neurosurg

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Delayed development of radiation vasculopathy of the brain stem confirmed by F-18 FDG PET in a case of anaplastic astrocytoma.

We present the imaging findings of a 38-year-old female patient who underwent resection and radiation therapy for an anaplastic astrocytoma in her left temporal lobe 12 years ago.

Magnetic resonance imaging (MRI) of the brain showed a new mass lesion in the left pontine region of the brain stem.

Therefore, an F-18 FDG brain PET scan was performed, which demonstrated no metabolic activity in the pontine lesion leading to the less common diagnosis of long-term postradiation vasculopathy.

This case illustrates the importance of considering the rare diagnosis of radiation-induced vasculopathy in the differential diagnosis when symptoms of recurrent brain tumor occur.

[MeSH-major] Brain Stem / radionuclide imaging. Cerebrovascular Disorders / etiology. Cerebrovascular Disorders / radionuclide imaging. Fluorodeoxyglucose F18. Radiation Injuries / etiology. Radiation Injuries / radionuclide imaging. Radiotherapy / adverse effects

[MeSH-minor] Adult. Astrocytoma / radionuclide imaging. Astrocytoma / radiotherapy. Female. Humans. Positron-Emission Tomography / methods. Radiopharmaceuticals. Time Factors

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17581336.001).

[ISSN] 0363-9762

[Journal-full-title] Clinical nuclear medicine

[ISO-abbreviation] Clin Nucl Med

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance.

EXPERIMENTAL DESIGN: In this study, we examined the expression levels of 365 mature human miRNAs in 12 malignant gliomas, including 8 glioblastomas and 4 anaplastic astrocytomas, using TaqMan real-time quantitative PCR arrays.

RESULTS: Expression profiles in glioblastomas and anaplastic astrocytomas suggested that 16 miRNAs were candidate markers associated with the malignant progression of gliomas.

Both miRNAs showed increased expression levels in glioblastomas relative to both anaplastic astrocytomas and normal brains in the validation study.

[MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics. MicroRNAs / genetics

Genetic Alliance. consumer health - Glioblastoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20601442.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN196 microRNA, human; 0 / MicroRNAs

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic oligoastrocytoma in Turcot syndrome.

Turcot syndrome (TS), a rare variant of hereditary non-polyposis colorectal cancer (HNPCC), is characterized by familial clustering of cancer of the large bowel, extracolonic body sites and brain.

We report a 72 year old woman with anaplastic oligoastrocytoma in the setting of TS.

Careful analysis of tumor DNA is required to exclude the chance occurrence of a brain tumor in HNPCC kindreds and increase our understanding of the pathogenesis of the disease.

[MeSH-major] Astrocytoma / complications. Colorectal Neoplasms, Hereditary Nonpolyposis / complications

Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.

Genetic Alliance. consumer health - Oligoastrocytoma.

Genetic Alliance. consumer health - Turcot syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Science. 1997 Feb 14;275(5302):967-9 [9020077.001]

[Cites] J Mol Diagn. 2000 Feb;2(1):20-8 [11272898.001]

[Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):75-81 [10337989.001]

[Cites] Gastroenterology. 1993 May;104(5):1535-49 [8482467.001]

[Cites] Genomics. 1994 Dec;24(3):516-26 [7713503.001]

[Cites] Nat Genet. 1996 Nov;14(3):255-7 [8896552.001]

[Cites] Nature. 1996 Aug 8;382(6591):499-500 [8700220.001]

[Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]

[Cites] Nature. 1994 Sep 1;371(6492):75-80 [8072530.001]

[Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]

[Cites] Int J Cancer. 1996 Feb 8;65(4):422-5 [8621220.001]

[Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]

[Cites] N Engl J Med. 1996 Mar 14;334(11):736-7 [8594446.001]

[Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]

[Cites] Jpn J Clin Oncol. 2002 Jun;32(6):215-8 [12110639.001]

[Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]

[Cites] Hum Mol Genet. 2000 Jan 22;9(2):283-7 [10607839.001]

[Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]

[Cites] Nervenarzt. 2002 Feb;73(2):177-82 [11975096.001]

[Cites] J Neurosurg. 1999 May;90(5):946-50 [10223463.001]

[Cites] Int J Cancer. 1995 Dec 20;64(6):430-3 [8550246.001]

[Cites] Nat Genet. 1999 Oct;23(2):142-4 [10508506.001]

[Cites] J Med Genet. 1995 Nov;32(11):909-12 [8592341.001]

[Cites] Nature. 1994 Mar 17;368(6468):258-61 [8145827.001]

[Cites] Oncogene. 1997 Dec 4;15(23):2877-81 [9419979.001]

(PMID = 19495563.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / Mismatch Repair Endonuclease PMS2; EC 3.6.1.3 / MutL Protein Homolog 1; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.

PURPOSE: Therapy for high-grade gliomas remains unsatisfactory.

We conducted a Phase II trial of these agents in combination with filgrastim (G-CSF) in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.

Hematologic toxicity was common with 25 /% of patients experiencing grade III or IV leukopenia despite G-CSF support.

CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma.

The significant hematotoxicity encountered, however, cannot justify further investigation of this combination in patients with high grade brain tumors.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy

Genetic Alliance. consumer health - Glioblastoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Filgrastim .

Hazardous Substances Data Bank. Topotecan .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):980-6 [12095566.001]

[Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]

[Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]

[Cites] Oncologist. 2003;8(1):76-82 [12604734.001]

[Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]

[Cites] J Clin Oncol. 1996 Jun;14(6):1964-5 [8656268.001]

[Cites] Ann Oncol. 2001 Jul;12(7):923-7 [11521796.001]

[Cites] J Clin Oncol. 2001 Apr 1;19(7):1893-900 [11283120.001]

[Cites] Cancer Res. 1993 Feb 15;53(4):725-7 [8428353.001]

[Cites] J Clin Oncol. 1995 Sep;13(9):2230-7 [7545219.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

[Cites] Cancer Chemother Pharmacol. 2001 Sep;48(3):188-96 [11592339.001]

[Cites] Ann Oncol. 1996 Feb;7(2):205-7 [8777179.001]

[Cites] J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20 [1331485.001]

[Cites] J Clin Oncol. 1998 Jun;16(6):2032-7 [9626200.001]

[Cites] J Clin Oncol. 1995 Aug;13(8):2066-71 [7636549.001]

[Cites] Biometrics. 1993 Sep;49(3):741-52 [8241370.001]

[Cites] J Clin Oncol. 1994 Mar;12(3):539-43 [8120551.001]

[Cites] J Clin Oncol. 1996 Feb;14(2):600-9 [8636777.001]

[Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]

[Cites] Drugs. 1995 Jan;49(1):11-9 [7705211.001]

[Cites] Cancer. 2001 Jan 15;91(2):417-22 [11180089.001]

[Cites] J Clin Oncol. 1998 Jun;16(6):2188-94 [9626220.001]

[Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]

[Cites] Expert Opin Pharmacother. 2001 Mar;2(3):491-505 [11336601.001]

[Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):113-9 [11516860.001]

(PMID = 15735921.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.

OBJECT: To investigate the prognostic significance of the volumetrically assessed extent of resection on time to tumor progression (TTP), overall survival (OS), and tumor recurrence patterns, the authors retrospectively analyzed preoperative and postoperative tumor volumes in 102 adult patients from the time of the initial resection of a hemispheric anaplastic astrocytoma (AA).

In contrast to low-grade gliomas, there was no statistically significant relationship between the extent of resection and histological characteristics at the time of recurrence, that is, tumor Grade III compared with Grade IV.

[MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / pathology

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16871879.001).

[ISSN] 0022-3085

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Contrast Media

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Salvage chemotherapy in progressive high-grade astrocytoma.

INTRODUCTION: Despite aggressive multidisciplinary interventions, patients with high-grade astrocytomas experience tumour progression or recurrence.

MATERIALS AND METHODS: A retrospective review of relevant clinical and radiographic information of patients who received at least one cycle of salvage chemotherapy for progressive high-grade astrocytoma at the National Cancer Center, Singapore, from March 2004 to September 2006, was conducted.

Patients underwent regular assessment with clinical examination and magnetic resonance brain imaging to gauge response to salvage chemotherapy.

RESULTS: Twenty-four patients (13 glioblastomas, 11 anaplastic astrocytomas) had received chemotherapy as salvage treatment following progression of their high-grade astrocytoma.

For patients with anaplastic astrocytoma, the 12-month survival rate was 73%.

CONCLUSION: Durable disease control and prolonged survival were seen in a significant portion of selected patients with progressive high-grade astrocytoma who received salvage chemotherapy.

[MeSH-major] Astrocytoma / drug therapy. Glioblastoma / drug therapy. Salvage Therapy / methods

[MeSH-minor] Adult. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies. Singapore. Survival Analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17549281.001).

[ISSN] 0304-4602

[Journal-full-title] Annals of the Academy of Medicine, Singapore

[ISO-abbreviation] Ann. Acad. Med. Singap.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Singapore

[Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.

AIMS: To investigate the correlation between O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma.

RESULTS: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss.

By Cox multivariate analysis, tumour grade and MGMT promoter methylation correlated with time to progression (p<0.05); MGMT promoter methylation correlated with superior overall survival in AA/AOA but not in glioblastoma.

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic

Genetic Alliance. consumer health - Glioblastoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18945611.001).

[ISSN] 1879-0852

[Journal-full-title] European journal of cancer (Oxford, England : 1990)

[ISO-abbreviation] Eur. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Postoperative regression of desmoplastic infantile astrocytoma].

Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG) is a rare tumor that is usually located superficially with a large cystic component.

In the central portion of the tumor, anaplastic features, such as necrosis, mitosis, and high nucleus-cytoplasmic ratio, were noticed.

Diagnosis was DIA.

[MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery

Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19048924.001).

[ISSN] 0301-2603

[Journal-full-title] No shinkei geka. Neurological surgery

[ISO-abbreviation] No Shinkei Geka

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genome-wide oligonucleotide microarray analysis of gene-expression profiles of Taiwanese patients with anaplastic astrocytoma and glioblastoma multiforme.

The gene-expression profiles of approximately 20,000 genes from 4 anaplastic astrocytomas (AAs), 7 glioblastoma multiformes (GBMs), and 1 nontumor brain (NB) were analyzed by in situ-synthesized 60-mer oligonucleotide microarray.

[MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genome, Human. Glioblastoma / metabolism

Genetic Alliance. consumer health - Glioblastoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18812569.001).

[ISSN] 1087-0571

[Journal-full-title] Journal of biomolecular screening

[ISO-abbreviation] J Biomol Screen

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Primers; 0 / Oligonucleotides

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intraventricular pleomorphic xanthoastrocytoma with anaplastic features.

However, considering the overall histopathological picture, a final diagnosis of PXA with anaplastic features was made.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology

[MeSH-minor] Diagnosis, Differential. Glioblastoma / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged

Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20051018.001).

[ISSN] 1440-1789

[Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology

[ISO-abbreviation] Neuropathology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Clinicopathologic study of pilocytic astrocytoma].

OBJECTIVE: To study clinicopathologic features, treatment and prognosis of pilocytic astrocytoma (PA).

One case had anaplastic features.

All cases showed diffuse positive staining for GFAP and low expression for Ki-67, except 1 anaplastic tumor with 10% Ki-67 indices.

CONCLUSIONS: PA is a benign, WHO grade I tumor with favorable prognosis, and does not require radiotherapy after total resection.

The tumor can be mistaken as higher-grade astrocytoma when involving the subarachnoid space, and with cytological atypia, leading to unnecessary radiotherapy after surgery.

The outcome for patients with brainstem tumor or anaplastic PA is poor.

[MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Glial Fibrillary Acidic Protein / genetics. Recurrence

Genetic Alliance. consumer health - Pilocytic astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19094585.001).

[ISSN] 0529-5807

[Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology

[ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC).

PURPOSE: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze (18)F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS).

These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined.

[MeSH-major] Astrocytoma / diagnostic imaging. Brain Neoplasms. Fluorodeoxyglucose F18. Imaging, Three-Dimensional / methods. Organizations. Positron-Emission Tomography / methods

[MeSH-minor] Adolescent. Brain / metabolism. Brain / pathology. Child. Child, Preschool. Clinical Trials, Phase I as Topic. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Phantoms, Imaging. Prognosis. Recurrence. Survival Rate

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]

[Cites] AJNR Am J Neuroradiol. 2007 Apr;28(4):603-7 [17416804.001]

[Cites] Mol Imaging Biol. 2006 May-Jun;8(3):141-50 [16534552.001]

[Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]

[Cites] Neurosurgery. 1996 Sep;39(3):470-6; discussion 476-7 [8875476.001]

[Cites] J Clin Oncol. 2006 Jul 10;24(20):3234-44 [16829647.001]

[Cites] Radiology. 1995 Apr;195(1):47-52 [7892494.001]

[Cites] J Clin Oncol. 2005 May 1;23 (13):3030-7 [15860860.001]

[Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]

[Cites] Clin Positron Imaging. 2000 Jul;3(4):152 [11150755.001]

[Cites] J Neurooncol. 2000 Sep;49(2):157-63 [11206011.001]

[Cites] J Comput Assist Tomogr. 1997 Jul-Aug;21(4):554-66 [9216759.001]

[Cites] Neuroimaging Clin N Am. 2002 Nov;12 (4):615-26 [12687915.001]

[Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]

[Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]

[Cites] J Neurosurg. 1985 Jun;62(6):816-22 [2987440.001]

(PMID = 18425516.001).

[ISSN] 1619-7070

[Journal-full-title] European journal of nuclear medicine and molecular imaging

[ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging

[Language] eng

[Grant] United States / NCI NIH HHS / CA / UM1 CA081457; United States / PHS HHS / / U01 A 81457

[Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidences of leptomeningeal dissemination.

CASE REPORT: A case of a non-anaplastic pleomorphic xanthoastrocytoma (PXA) presenting with leptomeningeal dissemination (LMD) affecting a 9-year-old girl is presented.

CONCLUSION: To our knowledge, this is the first case of a non-anaplastic PXA presenting with disseminated disease.

[MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Meningeal Neoplasms / complications. Neoplasm Recurrence, Local / etiology

Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]

[Cites] Neuropathol Appl Neurobiol. 1987 Nov-Dec;13(6):481-7 [3447073.001]

[Cites] Childs Nerv Syst. 2004 Feb;20(2):119-22 [14669022.001]

[Cites] J Neurooncol. 2001 Mar;52(1):63-72 [11451204.001]

[Cites] Histopathology. 1998 Apr;32(4):375-8 [9602336.001]

[Cites] Ann Neurol. 1985 Aug;18(2):217-21 [4037762.001]

[Cites] Brain Pathol. 1993 Jul;3(3):269-74 [8293186.001]

[Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1082-6 [9870856.001]

[Cites] Childs Nerv Syst. 2003 Apr;19(4):197-203 [12682758.001]

(PMID = 16369851.001).

[ISSN] 0256-7040

[Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

[ISO-abbreviation] Childs Nerv Syst

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.

To extend our understanding of potential stepwise genetic alterations that may underlie tumor progression from low-grade astrocytomas to glioblastomas, histopathologic and comparative genomic hybridization analyses were performed on tumor specimens from 68 primary lesions, including 40 glioblastomas, 10 anaplastic and 18 low-grade astrocytomas.

The number of aberrations per case increased towards the higher grade tumors (grade II: 1.66+/-1.49; grade III: 2.80+/-1.68; grade IV: 3.02+/-1.07; F=6.955, p=0.002).

A gain of 7/7q was common and the most frequently seen aberration in low-grade astrocytomas, whereas loss of 10q was the most frequently seen anomaly in anaplastic astrocytomas and glioblastomas.

Chromosome 10/10q deletion and combination of 1p, 19q and 17p deletions were specific to high-grade astrocytic tumors.

[MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosome Deletion. Glioblastoma / genetics

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Acta Neurol Belg. 2002 Jun;102(2):53-62 [12161900.001]

[Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]

[Cites] Cancer Res. 1994 Mar 15;54(6):1397-401 [8137236.001]

[Cites] Neurol Med Chir (Tokyo). 2003 Jan;43(1):12-8; discussion 19 [12568317.001]

[Cites] J Neuropathol Exp Neurol. 2002 Apr;61(4):321-8 [11939587.001]

[Cites] Mol Carcinog. 2003 Jan;36(1):6-14 [12503074.001]

[Cites] Hum Genet. 1993 Sep;92(2):169-74 [8370584.001]

[Cites] Front Biosci. 2003 May 01;8:e281-8 [12700122.001]

[Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]

[Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]

[Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]

[Cites] Anticancer Res. 1994 Mar-Apr;14(2A):577-9 [8017863.001]

[Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]

[Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]

[Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]

[Cites] Genes Chromosomes Cancer. 2005 Jan;42(1):68-77 [15472895.001]

[Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]

[Cites] Clin Neurol Neurosurg. 1997 May;99(2):117-23 [9213056.001]

[Cites] Neurosurg Rev. 2004 Jan;27(1):58-64 [12845540.001]

[Cites] Am J Pathol. 1994 Jun;144(6):1203-18 [8203461.001]

[Cites] Oncogene. 1997 Jun 19;14(24):2927-33 [9205099.001]

[Cites] Cancer Lett. 1999 Jan 8;135(1):61-6 [10077222.001]

[Cites] Br J Cancer. 1996 Feb;73(4):424-8 [8595154.001]

[Cites] Int J Cancer. 1999 Apr 20;84(2):150-4 [10096247.001]

[Cites] Int J Oncol. 2002 Nov;21(5):1141-50 [12370766.001]

[Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]

[Cites] Hum Pathol. 2000 May;31(5):608-14 [10836301.001]

[Cites] Virchows Arch. 1995;427(2):113-8 [7582239.001]

[Cites] Cancer Res. 1994 Dec 15;54(24):6353-8 [7987828.001]

(PMID = 17387387.001).

[ISSN] 1219-4956

[Journal-full-title] Pathology oncology research : POR

[ISO-abbreviation] Pathol. Oncol. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].

The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse.

The main laboratory test abnormalities (total incidence and incidence of grade 3/4 change) were lymphocytopenia (50%, 25%), neutropenia (47%, 6%), leukopenia (38%, 3%), thrombocytopenia (31%, 9%), and increased GPT (25%, 3%).

Temozolomide was shown to have good efficacy and tolerability in patients with anaplastic astrocytoma at first relapse.

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16969025.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.

We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ).

[MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Frontal Lobe. Genes, p53 / genetics. Germ-Line Mutation. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

Hazardous Substances Data Bank. DACARBAZINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2010 Wiley-Liss, Inc.

[ErratumIn] Pediatr Blood Cancer. 2011 Mar;56(3):509. Nariata, Yoshitaka [corrected to Narita, Yoshitaka]

(PMID = 20658636.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.

BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).

Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3).

[MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

[MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.

Genetic Alliance. consumer health - Oligodendroglioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19197992.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m2/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles.

Grade 3 and 4 lymphopenia occurred in 53% and 47% of patients, respectively.

[MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.

Genetic Alliance. consumer health - Oligoastrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. DACARBAZINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18317968.001).

[ISSN] 1532-4192

[Journal-full-title] Cancer investigation

[ISO-abbreviation] Cancer Invest.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.

PURPOSE: To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma.

Grade 3-4 toxicities were observed in 14 patients (48%).

The primary study endpoint was the 23-month (700-day) survival, the median survival of patients with anaplastic astrocytoma in a previous North Central Cancer Treatment Group trial.

CONCLUSION: Our results have demonstrated that pre-RT chemotherapy with this regimen is insufficiently active in patients with anaplastic astrocytoma.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Oral cancer.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. Carmustine .

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15667956.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic oligo-astrocytoma occurring after resection of a cerebral cavernous malformation; malignant transformation? Case report and review on etiology.

Histological examination showed an anaplastic oligo-astrocytoma.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hemangioma, Cavernous, Central Nervous System / complications. Hemangioma, Cavernous, Central Nervous System / surgery. Postoperative Complications / pathology

[MeSH-minor] Aged. Astrocytes / pathology. Brain / diagnostic imaging. Brain / pathology. Brain / physiopathology. Cell Transformation, Neoplastic. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / physiopathology. Neurosurgical Procedures / adverse effects. Oligodendroglia / pathology. Tomography, X-Ray Computed

Genetic Alliance. consumer health - Cerebral Cavernous Malformation.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - After Surgery.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neuropathol Exp Neurol. 1996 Nov;55(11):1124-33 [8939195.001]

[Cites] J Neuropathol Exp Neurol. 1958 Apr;17(2):392-8 [13525999.001]

[Cites] Am J Surg Pathol. 1998 Jul;22(7):816-26 [9669344.001]

[Cites] Surg Neurol. 2003 Jul;60(1):80-2; discussion 83 [12865022.001]

[Cites] Arch Neurol. 2005 Apr;62(4):653-8 [15824268.001]

[Cites] J Neurosurg. 1975 Jul;43(1):108-11 [1141977.001]

[Cites] Acta Neurochir (Wien). 1979;50(3-4):305-9 [517201.001]

[Cites] J Neurosurg. 1985 Jan;62(1):145-7 [3964848.001]

[Cites] Neurosurgery. 2000 May;46(5):1179-91; discussion 1191-2 [10807251.001]

[Cites] Acta Neurochir (Wien). 1995;133(3-4):169-73 [8748761.001]

[Cites] Scott Med J. 1960 Aug;5:342-5 [13822860.001]

[Cites] J Neurosurg. 1968 Mar;28(3):241-51 [5643915.001]

[Cites] J Neurosurg. 1990 May;72(5):798-805 [2182794.001]

[Cites] Neurology. 1995 Mar;45(3 Pt 1):492-7 [7898703.001]

[Cites] Pathol Int. 1998 Feb;48(2):109-14 [9589474.001]

[Cites] J Neurosurg. 1991 Oct;75(4):589-66 [1885977.001]

[Cites] Acta Neurochir (Wien). 1986;83(1-2):38-46 [3799248.001]

[Cites] J Neurosurg. 1995 Oct;83(4):682-9 [7674019.001]

[Cites] Acta Neurochir (Wien). 1996;138(5):590-1 [8800336.001]

[Cites] Neurosurgery. 2002 Apr;50(4):838-42; discussion 842 [11904036.001]

[Cites] Acta Neuropathol. 2000 Jul;100(1):101-5 [10912927.001]

[Cites] J Neurosurg. 1982 Mar;56(3):430-4 [7057243.001]

[Cites] Am J Pathol. 1999 May;154(5):1345-52 [10329587.001]

(PMID = 19777285.001).

[ISSN] 1432-1459

[Journal-full-title] Journal of neurology

[ISO-abbreviation] J. Neurol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.

PURPOSE: To review interpathologist diagnosis variability and survival of children treated for either anaplastic mixed glioma (AMG) or anaplastic oligodendroglioma (AO) with surgery, irradiation and chemotherapy.

PATIENTS AND METHODS: Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.

However, central review established that only nine of 26 children had AMG: either mixed oligoastrocytoma (MOA) or anaplastic mixed oligoastrocytoma (AOA) and only one had AO.

CONCLUSION: Diagnosis of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy.

[MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy

[MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Survival Analysis

Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.

Genetic Alliance. consumer health - Oligodendroglioma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]

[Cites] Hepatology. 1991 Nov;14(5):751-5 [1937381.001]

[Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]

[Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]

[Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]

[Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]

[Cites] J Neurooncol. 1994;21(3):255-65 [7699420.001]

[Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]

[Cites] J Clin Oncol. 2003 Jan 15;21(2):251-5 [12525516.001]

[Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]

[Cites] J Neurooncol. 2003 May;63(1):49-54 [12814254.001]

[Cites] J Chronic Dis. 1967 Aug;20(8):637-48 [4860352.001]

[Cites] J Neurooncol. 1988;6(1):9-23 [3294353.001]

[Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]

[Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]

[Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]

[Cites] Pediatr Neurosurg. 2003 Sep;39(3):114-21 [12876389.001]

[Cites] Curr Treat Options Oncol. 2000 Dec;1(5):459-68 [12057153.001]

[Cites] J Neuropathol Exp Neurol. 1994 Nov;53(6):559-71 [7964897.001]

[Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]

[Cites] J Acquir Immune Defic Syndr. 1990;3 Suppl 2:S120-3 [2231292.001]

[Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]

[Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]

(PMID = 17252186.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article; Randomized Controlled Trial

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.

PURPOSE: To describe a patient with a history of epithelial basement membrane dystrophy who developed symptomatic corneal verticillata after vandetanib therapy for anaplastic astrocytoma.

RESULTS: A 48-year-old female patient with a history of anaplastic astrocytoma status post resection, external beam radiation, and chemotherapy presented with glare symptoms, decreased contrast sensitivity, and increased lacrimation after approximately 12 months of therapy with the anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor, vandetanib.

[MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Corneal Diseases / chemically induced. Neoplasm Recurrence, Local / drug therapy. Piperidines / adverse effects. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Corneal Disorders.

Hazardous Substances Data Bank. SODIUM CHLORIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19512898.001).

[ISSN] 1536-4798

[Journal-full-title] Cornea

[ISO-abbreviation] Cornea

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Ointments; 0 / Piperidines; 0 / Quinazolines; 451W47IQ8X / Sodium Chloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.2.1.4 / Cellulase; EC 3.2.1.4 / carboxymethylcellulase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.

We describe the case of a patient with transcobalamin II deficiency, hypogammaglobulinemia, absent corpus callosum, and mental retardation who presented at an early age with colorectal cancer and multifocal anaplastic astrocytoma.

[MeSH-major] Abnormalities, Multiple / genetics. Adenosine Triphosphatases / genetics. Astrocytoma / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics

[MeSH-minor] Adolescent. Adult. Brain / pathology. Child. Child, Preschool. Colon / pathology. Corpus Callosum / pathology. DNA Mutational Analysis. Humans. Immunohistochemistry. Intellectual Disability / genetics. Intellectual Disability / pathology. Male. Mutation. Pedigree. Polymorphism, Single Nucleotide. Transcobalamins / deficiency

Genetic Alliance. consumer health - Colorectal Cancer.

Genetic Alliance. consumer health - Agenesis of the Corpus Callosum.

Genetic Alliance. consumer health - Hereditary Cancer.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

Genetic Alliance. consumer health - Mental Retardation.

Genetic Alliance. consumer health - Transcobalamin II deficiency.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Vitam Horm. 2000;59:337-66 [10714245.001]

[Cites] Oncogene. 2000 Mar 23;19(13):1719-23 [10763829.001]

[Cites] Am J Pathol. 2002 Jun;160(6):1953-8 [12057899.001]

[Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]

[Cites] Am J Hum Genet. 2004 May;74(5):954-64 [15077197.001]

[Cites] Cancer Res. 2004 Jul 15;64(14):4721-7 [15256438.001]

[Cites] Cancer Res. 2006 Aug 1;66(15):7810-7 [16885385.001]

[Cites] Nature. 1994 Sep 1;371(6492):75-80 [8072530.001]

[Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]

[Cites] Arch Dis Child. 1995 Mar;72(3):237-8 [7741573.001]

[Cites] Curr Probl Surg. 2005 Apr;42(4):195-256 [15821699.001]

[Cites] Clin Invest Med. 2005 Oct;28(5):267-82 [16265999.001]

[Cites] Hum Mutat. 2006 May;27(5):490-5 [16619239.001]

[Cites] Br J Haematol. 1992 Jan;80(1):117-20 [1536799.001]

(PMID = 17993636.001).

[ISSN] 1522-8517

[Journal-full-title] Neuro-oncology

[ISO-abbreviation] Neuro-oncology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcobalamins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 6.5.1.- / DNA Repair Enzymes

[Other-IDs] NLM/ PMC2600843

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).

BACKGROUND: In a previous randomised EORTC study on adjuvant dibromodulcitol (DBD) and bichloroethylnitrosourea (BCNU) in adults with glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), a clinically significant trend towards a longer overall survival (OS) and a progression-free survival (PFS) was observed in the subgroup of AA.

METHODS: Continuation of the previous phase III trial for newly diagnosed AA according to the local pathologist.

Central pathology review of grade 3 tumours remains crucial.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18248979.001).

[ISSN] 0959-8049

[Journal-full-title] European journal of cancer (Oxford, England : 1990)

[ISO-abbreviation] Eur. J. Cancer

[Language] eng

[Grant] United States / NCI NIH HHS / CA / U10 CA 11488

[Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] LJ2P1SIK8Y / Mitolactol; U68WG3173Y / Carmustine

[Investigator] Afra D; Maat B; Hildebrand J; de Wit O; Frenay F; Chatel M; Rivier I; Taphoorn M; Delattre JY; de Tribolet N; Stupp R; Punt J; Garfield J; Chinot O; van den Bent M; Lahrmann H; Cristo C; Mouchamps M; Haferkamp G; Bravo Marques J

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.

The purpose of this study was to evaluate combination chemotherapy with Gliadel wafer and carboplatin in patients with high-grade, malignant glioma.

Fourteen (88%) patients had glioblastoma multiforme and 2 (12%) had anaplastic astrocytoma.

No grade 3 or 4 toxicities were noted in this study.

[MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carboplatin / therapeutic use. Decanoic Acids / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Polyesters / therapeutic use

Genetic Alliance. consumer health - Glioblastoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Carmustine .

Hazardous Substances Data Bank. CARBOPLATIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Curr Opin Neurol. 2000 Dec;13(6):619-25 [11148660.001]

[Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]

[Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]

[Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]

[Cites] Neurosurgery. 1992 Feb;30(2):223-7 [1312230.001]

[Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]

[Cites] Cancer Res. 1998 Feb 15;58(4):672-84 [9485020.001]

[Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]

[Cites] Neuro Oncol. 2001 Oct;3(4):246-50 [11584894.001]

[Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]

[Cites] Cancer Chemother Pharmacol. 1997;39(4):376-9 [9025780.001]

[Cites] J Control Release. 1999 Aug 27;61(1-2):21-41 [10469900.001]

[Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]

(PMID = 15937647.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Drug Implants; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine